Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model

BACKGROUND: T cells have been recognized as core effectors for cancer immunotherapy. How to restore the anti-tumor ability of suppressed T cells or improve the lethality of cytotoxic T cells has become the main focus in immunotherapy. Bispecific antibodies, especially bispecific T cell engagers (TCE...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Immunother Cancer
Hlavní autoři: Ma, Huilin, Wang, Hanwen, Sové, Richard J, Wang, Jun, Giragossian, Craig, Popel, Aleksander S
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2020
Témata:
Immunotherapy Biomarkers
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7454244/
https://ncbi.nlm.nih.gov/pubmed/32859743
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001141
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky